Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19

Pages: 71 Published: May 31, 2021 Report Code: GDHCHT279

The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.

Scope

The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials that were captured in the database as of April 22, 2021. The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.

Reasons to Buy

Understand the global COVID-19 landscape

The trends of vaccine COVID-19 clinical trials

The trends of therapeutic COVID-19 clinical trials

A closer look at the impact of the pandemic on non-COVID-19 trials

Table of Contents

Executive Summary

Introduction

Analysis of COVID-19 Clinical Trials

COVID-19 Clinical Trials for Vaccines

COVID-19 Clinical Trials for Therapeutics

Impact of COVID-19 on Clinical Trials

Key Findings

Appendix

List of Tables

List of Tables

Table 1: Top Countries with COVID-19 Key Stats

List of Figures

List of Figures

Figure 1: Impact of COVID-19

Figure 2: Top Countries in COVID-19 Key Stats

Figure 3: Landscape of Pipeline Candidates for COVID-19, by Phase

Figure 4: Landscape of Vaccines Candidates for COVID-19, by Phase

Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month

Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country

Figure 7: Single Country COVID-19 Clinical Trials, By Region & Phase

Figure 8: Multinational Country COVID-19 Clinical Trials, By Region & Phase

Figure 9: COVID-19 Clinical Trial Sites, by Region

Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State

Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status

Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials

Figure 15: Top Reasons for Terminated Trials, by Phase

Figure 16: Top Reason for Terminated Trials, by Sponsor Type

Figure 17: COVID-19 Clinical Trials by Vaccine, by Month

Figures 18 & 19: Vaccine COVID-19 Clinical Trials, by Phase & Status

Figure 20: Vaccine COVID-19 Clinical Trials, by Sponsor Type

Figure 21: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figure 22: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figures 23 & 24: Pfizer/BioNTech’s Tozinameran (Comirnaty), by Status & Phase

Figures 25 & 26: Moderna’s mRNA-1273, by Status & Phase

Figures 27 & 28: Johnson & Johnson’s JNJ-78436735, by Status & Phase

Figures 29 & 30: AstraZeneca’s Covishield (Vaxzevria), by Status & Phase

Figures 31 & 32: Bharat Biotech’s Covaxin, by Status & Phase

Figures 33 & 34: CanSino Biologics’ Convidecia, by Status & Phase

Figures 35 & 36: SinoVac Biotech’s CoronaVac, by Status & Phase

Figure 37: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines

Figure 38: Clinical Trial Start Date to First Approval for Vaccines

Figure 39: COVID-19 Therapeutic Clinical Trials, by Month

Figure 40 & 41: Therapeutic COVID-19 Clinical Trials, by Phase & Status

Figure 42: Therapeutic COVID-19 Clinical Trials, by Sponsor Type

Figure 43: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figure 44: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figures 45 & 46: Gilead Sciences’ Remdesivir (Veklury), by Status & Phase

Figures 47 & 48: Fujifim Toyama Chemical’s Favipiravir, by Status & Phase

Figures 49 & 50: Eli Lilly’s Bamlanivimab, by Status & Phase

Figures 51 & 52: Regeneron’s Casirivimab + Imdevimab, by Status & Phase

Figures 53 & 54: Eli Lilly’s Baricitinib, by Status & Phase

Figures 55 & 56: CytoDyn’s Leronlimab, by Status & Phase

Figure 57: Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs

Figure 58: Clinical Trials Disrupted Due to COVID-19

Figures 59 & 60: Disrupted Clinical Trials, by Reason

Figure 61 & 62: Disrupted Clinical Trials, by Therapy Area

Figure 63: Disrupted Clinical Trials Activities

Figure 64: Disrupted Clinical Trials, by Top Sponsors

Figure 65: Resumed Clinical Trials, by Top Five Therapy Areas

$695

Can be used by individual purchaser only

$2,085

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022